cancer-summit-neuro-congress-2018-tracks

Allied Journal of Medical Research

Volume 2

Page 22

Note:

allied

academies

CANCER THERAPY AND ONCOLOGY

NEUROLOGY AND BRAIN DISORDERS

International Conference on

J u n e 2 1 - 2 2 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

FXYD3: A PROMISING BIOMARKER

FOR CANCER TREATMENT

Chia chi Liu

Sydney Medical School - University of Sydney, Australia

Kolling Medical Research Institute - Royal North Shore Hospital, Australia

asy access to the Na

-K

pump in the cell surface membrane and the

critical dependence of cell survival on the pump has made it is an

attractive therapeutic target incancer. Useof cardiacglycosides havebeen

explored but has turned out to have limited utility due cardiac toxicity of

the drugs. As an alternative we have examined if targeting FXYD proteins

that associate closely with the Na

-K

pump molecular complex might

be useful. FXYD3 is of interest because it is markedly over-expressed in

several common cancers and we have shown that several FXYD proteins,

including FXYD3, are critical for reversal of glutathionylation of the β1

-K

pump subunit, an oxidativemodification that inhibits pump activity.

We hypothesized that FXYD3 protein overexpression protects pump

function against inhibition by the high levels of oxidative stress in cancer

cells typically encounter and a reduction in FXYD3 expression levels would

sensitize cells to chemotherapy and radiotherapy that largely induce

cell kill by increasing oxidative stress. In light of the reported treatment

resistance of overexpressing FXYD3 cancers, results suggest silencing

wild type proteins may greatly strengthen the efficacy of treatments that

increase oxidative stress within tumors. Such increases are commonly

seen with radiotherapy and chemotherapeutic agents. This ongoing study

endeavors to develop amalgamated novel treatments for cancer patients

while alleviating side effects associated with traditional therapy; advance

diagnosis and improve overall patient well-being.

Chia chi Liu is Senior Research Fellow and

Molecular Biologist with expertise in oxidative

protein chemistry at University of Sydney. She

was a Biochemistry Lecturer in Taipei Medical

University Taiwan. She completed MSc in Cell

and Molecular Biology at Taipei Medical Uni-

versity Taiwan, followed by second MSc in Bio-

technology, University of New South Wales. She

then completed her PhD within the Department

of Chemistry and Biomolecular Science, Mac-

quarie University. Her core focus is investigating

the relationship between oxidative stress and

the sodium pump function. Her research inter-

ests include the development of new diagnostic

methods for oxidative damage of the pump; the

discovery of new drugs for heart disease; and

the design of novel therapeutic proteins for can-

cer treatment.

chiachi.liu@sydney.edu.au

BIOGRAPHY

Chia chi Liu, Allied J Med Res 2018, Volume 2